Objective: Inhibition by endothelin antagonist is a potential therapy in heart failure. However, the effect of endothelin inhibition during the development of heart failure has not been evaluated. The goal of our study was to examine the acute hemodynamic effects of the mixed endothelin receptor antagonist bosentan in the control state and at different stages of heart failure induced by right ventricular pacing (250 bpm) in conscious dogs. Methods: Nine dogs were chronically instrumented for the measurements of left ventricular pressure and its first derivative (dP/dt), cardiac output, left ventricular regional wall thickness and aortic pressure. Bosentan (3 mg / kg, i.v. bolus) and placebo were given at control, at 1 week of pacing (stage of left ventricular dysfunction with perserved cardiac output) and at 3 weeks of pacing (phase of heart failure with low cardiac output). Results: With the development of heart failure, baseline plasma endothelin level increased progressively. Placebo did not induce hemodynamic and plasma endothelin changes during the 30 min recording at any stage. At control, bosentan did not change hemodynamics. At 1 and 3 weeks of pacing, bosentan did not modify left ventricular myocardial function indices but reduced mean arterial pressure (by 762 and 861 mm Hg respectively, p,0.005). Bosentan increased stroke volume at 3 weeks of pacing only. Conclusions: Endothelin inhibition by endothelin antagonist bosentan, decreases aortic pressure in both early left ventricular dysfunction and in heart failure in contrast with the control state. In the phase of heart failure with low cardiac output, bosentan increases stroke volume. In the early left ventricular dysfunction, bosentan, by reducing arterial pressure, may limit the deterioration of cardiac function through a reduction of the workload imposed on the heart.
Introduction
which mediate most of the vasoconstrictor action of ET-1 [4, 5] are present on vascular smooth muscle cells and Endothelin-1 is one of the three isoforms of endothelin cardiac myocytes. ET-B receptors are present on vascular (ET) that can cause potent vasoconstriction [1] . ET-1 can endothelium, mediating the transient vasodilator response be produced by endothelial cells, vascular smooth muscle to ET [4, 5] and on vascular smooth muscle, participating cells and other cell types such as cardiac myocytes and in the vasoconstrictor effects of ET [6] [7] [8] . may contribute to the development of myocardial hy-
The pathophysiological importance of ET in experimenpertrophy [2, 3] . Two ET receptors (ie, ET-A and ET-B) tal and human heart failure (HF) is suggested by its plasma mediate the vascular effects of ET [4, 5] . ET-A receptors elevation [9, 10] . In HF, recent studies showed that systemic vasoconstriction was mediated in part by ET-1 and the ET-1 plasma levels were correlated with the degree of afterload, may thus be beneficial in HF. Indeed, the use of 2.2. Experimental protocol a mixed ET receptor antagonist in patients with HF with low cardiac output was shown to induce an improvement For each dog, the experimental protocol consisted of of the hemodynamic profile [11] . In contrast, little is three steps: first, before the induction of HF (control state), known concerning the contribution of ET in a less severe second, after one week of pacing (LV dysfunction with phase of HF and the effect of ET blockade has never been preserved cardiac output) and third after 3 weeks of pacing examined at this stage. Therefore, the goal of this study (HF with low cardiac output). During the three states, was to examine the acute hemodynamic effects of a mixed experiments were performed in dogs fully awake, lying ET receptor antagonist, bosentan, at different stages of HF quietly on their right side. induced by rapid ventricular pacing in chronically instrumented conscious dogs. weeks of pacing, after a 15-min stabilization period using halothane (1 % vol.). Under sterile conditions and subsequent to deactivation of the pacemaker, baseline through an incision in the fifth left intercostal space, measurements in sinus rythm were taken, then, placebo or catheters (Tygon, Norton Plastics, Akron, OH) were bosentan were injected. Placebo and bosentan were given implanted in the ascending aorta and the left atrium. A on different days with a separation period of 24 h. The first solid-state pressure gauge (P22, Konigsberg Instruments, day, placebo (7 ml of distilled water) was injected as an Pasadena, CA) was implanted in the left ventricle (LV) intravenous bolus and, 24 h later, bosentan was injected through the apex to measure LV pressure and the first also as an intravenous bolus (3 mg / kg). Hemodynamic derivative of LV pressure (LV dP/ dt). In eight dogs, one parameters were recorded in the basal state and every 5 pair of 5 MHz piezoelectric crystals was implanted to min during the 30 min period following drug or placebo measure posterior LV full wall thickness. For each pair, injection. After 3 weeks of pacing, 45 min after the one crystal was placed on the epicardium and the other intravenous injection of 3 mg / kg of bosentan, an additionwas advanced obliquely to the endocardial layer. To al bolus of 10 mg / kg of bosentan was injected intravenfurther characterize the changes in left ventricular and ously. The dose of 3 mg / kg of bosentan was based on the systemic hemodynamics induced by one week of pacing study of Teerlink et al [12] which demonstrates in normal and to dissect further the effects of bosentan, an aortic flow anesthetized dogs, that an intravenous injection of 3 mg / probe (Transonic Systems, Ithaca, NY) was implanted kg of bosentan prevents nearly completely the systemic around the root of the ascending aorta to measure cardiac vasoconstriction induced by big-ET-1 and the vasodilation output in five dogs. Five dogs only were instrumented induced by an ET-B receptor agonist sarafotoxin S6c. because of the risk of aortic rupture which usually inConsidering the volume of distribution of bosentan in dog: creases with prolongation of chronic instrumentation (over 0.27-0.38 l / kg (Hoffman-La-Roche, unpublished data), it 8 weeks in the current study). Stainless-steel pacing wires can be estimated that an intravenous injection of 3 mg / kg 25 were implanted on the right ventricle. A permanent of bosentan results in a concentration of 1-2 10 M in drainage tygon catheter (Norton Plastics, Akron, OH) was dog. placed in the left thoracic cavity. Catheters and leads were externalized infrascapularly, and the thoracotomy was 2.3. Data collection and analysis closed in layers. Burprenorphine (3 mg) was given subcutaneously when the dog had restored autonomic respiraAbsolute values of LV pressure were obtained by tion. The animals were given daily post-operative care. All calibrating the micromanometer in 378C water against a dogs were allowed to recover for 2-3 weeks.
Statham P23ID transducer (Gould Inc., Valley View, Ohio, USA) before implantation. of variance for repeated measures of the same parameters using a software (HEM v1.4, Notocord systems, Croissyover time was used to compare intergroup drug interacsur-Seine, France) and also recorded on a multi-task tions. After analysis of variance, comparisons between graphic recorder (MT-95000, Astro-Med Inc, RI) at a means were performed with contrast analysis. When only paper speed of 50 mm / sec. Left ventricular measurements two means were compared, a t-test was used. Statistical and aortic pressures obtained from the computer were significance was defined as p,0.05. verified by one of us (RC). For this purpose, 9-12 beat measurements were averaged and maximal and minimal rates of LV pressure changes (LV dP/dt max and LV dP/ dt 3. Results min) were derived from the LV pressure by use of operational amplifiers connected as differentiators with a 3.1. Baseline measurements before, one week and three frequency response of 700 Hz. To directly calibrate the weeks after pacing differentiator, a triangular wave signal was substituted for the pressure signals. End diastole was defined as the time Representative illustrations of waveforms from the same point when LV pressure began to rise just after the atrial animal in the control state, after one week and three weeks contraction. End systole was defined as the time point of pacing are displayed in Fig. 1 . Baseline hemodynamics occuring at LV dP/dt min. Stroke volume was calculated in the same 9 dogs studied in sinus rhythm in the three as the ratio of cardiac output / heart rate. Total peripheral stages are shown in Tables 1-3 . One week of pacing resistance was calculated as the ratio of (mean arterial induced a LV dysfunction characterized by a significant pressure2right atrial pressure) / cardiac output. Cardiac increase in LV end-diastolic pressure ( p,0.005) as comoutput measurements were obtained in 5 dogs. LV endpared with the control state and significant decreases in diastolic wall thickness was measured at the onset of LV mean aortic pressure ( p,0.005), LV dP/dt max ( p, contraction, indicated by the initial increase in LV dP/ dt. 0.005) and LV systolic wall thickening ( p,0.005). At this LV end-systolic wall thickness was measured at the time stage, heart rate, cardiac output and total peripheral point occuring at the peak negative LV dP/dt. Adequate resistance were not modified significantly. LV wall thickness measurements were obtained in 7 of the After three weeks of pacing, dogs developed HF which 8 dogs instrumented for that measurement. LV wall thickwas characterized by peripheral signs of congestive HF ness measurement was rejected for analysis in one dog (exertional dyspnea, ascites) and by a low cardiac output with a control systolic LV wall thickening below 15%. associated with greater alterations in LV regional wall thickness ( p,0.05 as compared with control state or 1 2.4. Plasma ET-1 and big-ET-1 assays week of pacing; Fig. 1 and Table 3 ). Heart rate increased significantly ( p,0.005 as compared with control state and To measure arterial plasma ET-1 and big-ET-1 levels, p,0.05 as compared with 1 week of pacing). Total blood samples were withdrawn from the aortic catheter at peripheral resistance was significantly increased as combaseline, after 15 and 30 min of bosentan or placebo pared with one week of pacing ( p,0.05). injection in the control state and after one and three weeks Baseline hormonal characteristics are shown in Table 4 . of pacing. The samples were collected in tubes containing After one week of pacing, mean plasma ET-1 level raised EDTA and were immediately placed on ice, and censignificantly (Table 4) . Between one and three weeks of trifuged at 48C; plasma was then stored at 2708C until pacing, plasma ET-1 levels increased further (but not assay. All samples from a single dog were analyzed in the significantly as compared with 1 week of pacing). Plasma same assay to avoid inter-assay variability. ET-1 was big-ET-1 did not increase at one week of pacing but determined with the polyclonal rabbit antiserum RAS 6901 increased significantly after three weeks of pacing as developed in our laboratory. The sensitivity of the assay compared with the control state and with one week of was 0.2 pg / tube. For measurement of big-ET-1, an Elisa pacing ( fore the injection of bosentan or placebo both after one pressure decreased in parallel. The other measured carweek and three weeks of pacing (Tables 2 and 3) . diovascular parameters remained unchanged. After one week of pacing, placebo infusion did not After three weeks of pacing, placebo infusion did not produce hemodynamic changes demonstrating the validity produce hemodynamic changes (Table 3) . Bosentan (3mg / of the experimental procedure (Table 2 ), whereas bosentan kg; i.v.) decreased mean aortic pressure (Table 3 and Fig.  administration (3mg / kg; i.v.) produced a decrease in mean 2, right panel). The effect was apparent 1 minute after the aortic pressure (Table 2 and Fig. 2, left panel) . The effect injection, progressively increased and became maximal at occured progressively, was apparent 3 min after the 25 min of infusion (from 8462 mm Hg at baseline to injection, became maximal at 15 min (from 8163 mm Hg 7362 mm Hg, p,0.001). It persisted until the end of the at baseline to 7362 mm Hg, p,0.001) and persisted until experiment. After bosentan, heart rate decreased signifithe end of the experiment (Fig. 2, left panel) . LV systolic cantly; stroke volume increased by 17% (from 12.860.6 ml at baseline to 14.360.6 ml) and total peripheral mg / kg administration of bosentan after three weeks of resistance decreased by 17% (from 4565 mm Hg/l/min at pacing. This additional dose did not produce larger effects baseline to 3964 mm Hg/l/min). The other measured on mean aortic pressure than the dose of 3 mg / kg since cardiovascular parameters remained unchanged throughout mean arterial pressure decreased from 8663 to 7863 mm the study (Table 3) .
Hg after the dose of 3 mg / kg and to 7762 mm Hg 30 min In order to verify that blockade of endothelin receptors after the dose of 10 mg / kg. During the same time frame, by bosentan was complete, an additional dose of 10 mg / kg heart rate decreased from 13364 to 12064 and to 12666 was injected intravenously in 6 dogs, following the 3 beats / min respectively. Similarly, LV dP/dt and cardiac Table 3 Hemodynamic and dimensional parameters in response to placebo and to bosentan (3 mg / kg, i.v.) at the stage of heart failure (3 weeks of right ventricular pacing) mg / kg of bosentan. Plasma big-ET-1 levels which were similar at baseline before the administration of placebo or bosentan remained unchanged after placebo or bosentan injection (Table 4) .
Discussion
The present study determined the hemodynamic effects of acute administrations of a mixed ET receptor antagonist, bosentan, at control and at different stages of development of HF induced by rapid ventricular pacing in chronically instrumented conscious dogs. In the control state, bosentan did not induce any change in hemodynamic parameters but at a stage of LV dysfunction, bosentan decreased the aortic pressure and consequently the workload of the heart. This result demonstrates the vasomotor effect of endothelin in the early phase of HF. At the stage of HF associated with low cardiac output, the hemodynamic effects of bosentan persisted and were associated with an increase in stroke volume.
Heart failure model and ET plasma levels
The model used in this study, particularly in the phase of HF, has been characterized in detail in previous studies [13] [14] [15] [16] [17] [18] [19] [20] . In contrast, the phase of LV dysfunction has been less characterized in the literature [21] . The present study characterizes further the early phase of HF showing, after one week of pacing, a marked alteration in LV systolic wall may explain a larger increase in ET-1 than in big-ET-1 in the first evidence that ET-1 contributes to vasoconstriction our study, one can quote changes in the conversion rate of in patients with severe chronic HF. However, a direct big-ET-1 to ET-1, an increased substrate availability and / comparison between our results and those obtained in or a decreased clearance in renal and pulmonary circulapatients must be made with caution, since patients with tions.
heart failure receive additional therapies, particularly angiotensin-converting enzyme inhibitors which may modify the endothelin system due to potential interaction between 4.2. Hemodynamic effects of bosentan in the control the endothelin and the renin-angiotensin systems [22, 24] . state
In addition to its potent vasocontractile effects, in vitro ET-1 is a positive inotropic agent on isolated heart muscle Haynes and Webb [8] found, in healthy subjects, that [25] ). This effect is mediated in a large part by ET-A local intra-arterial administration of the ET-1 receptor receptors [26] . ET-A density was shown to be increased in antagonist BQ-123 which selectively blocks ET-A re-HF in rats [27] . The up-regulation of ET-A receptors and ceptors, induced a forearm blood flow increase, suggesting the increase in plasma ET levels may provide an inotropic that ET-1 contributes to the maintenance of basal vascular support of the failing heart. It is thus possible to speculate tone. In our study, in the control state, bosentan was that, in HF, blockade of these receptors may produce a devoid of hemodynamic effect (Table 1 ). This suggests decrease in contractility. This was found in one study in that ET-1 plays a minor role (if any) in the maintenance of rats with HF treated with BQ-123 [27] . In contrast with vascular tone. Our results are in agreement with those of this hypothesis, a study with bosentan in dogs with HF Teerlink et al [22] who found in anesthetized rats no showed an increase in LV performance indices. In our significant change in blood pressure after administration of study, an increased stroke volume was observed in HF, bosentan. The discrepancy between these studies is probaprobably due to an improvement in systemic hemodybly due to the different blockade produced by bosentan namics because no change in LV myocardial function was (both ET-A and ET-B receptors) and by BQ-123 (ET-A found with bosentan in HF (since peak LV dP/dt and LV receptors only). It is possible that the blockade of ET-A systolic wall thickening did not change with an unchanged receptors alone increases ET plasma level which may in end-diastolic pressure). The absence of change in LV turn stimulates ET-B receptors, inducing a vasodilation myocardial function indices found in our study may be due which is known with the stimulation of these receptors to opposite factors acting on ventricular function (loading [4, 5] .
conditions, heart rate changes and contractility) leading to an unchanged LV myocardial function indices. After 4.3. Hemodynamic effects of bosentan in heart failure bosentan, in association with decreased mean aortic pressure, heart rate decreased in the phase of HF. Since One of the major findings of our study is the demonstraendothelin exerts positive chronotropic effect as shown in tion of the vasodilatory effect of bosentan in the phase of isolated tissues [28, 29] , its receptor blockade by bosentan LV dysfunction. Our results show that bosentan produces can be expected to reduce heart rate by blocking the effects marked decreases in aortic and ventricular systolic of endogenous ET. This was the case in our study. The pressures with a trend towards a decrease in total peripherabsence of tachycardia in spite of a decrease in aortic al resistance while cardiac output, heart rate and indices of pressure in response to bosentan was also probably due to myocardial performance, such as LV dP/dt max or LV a blunted baroreflex and a decreased sympathethic sensystolic wall thickening remained unchanged ( Table 2, Fig. sitivity which are known in this model [13, 17, 19 ,21] and 2 left panel). The decrease in mean aortic pressure clearly to an absence of sympathetic stimulation after ET antagosuggests that, in contrast with the control state, endogenous nist administration in heart failure [23, 30, 31] . ET-1 plays a role in the maintenance of the vascular tone at the stage of LV dysfunction. In the phase of heart failure, bosentan decreased mean aortic pressure, left 4.4. Plasma ET-1 and big-ET-1 changes induced by ventricular systolic pressure and total peripheral resistance.
bosentan Our results contrast with those of a past study in dogs with chronic HF induced by multiple intracoronary embolizaAfter bosentan, ET-1 plasma levels increased to a tions [23] , where bosentan reduced systemic vascular similar extent at the three stages without any effect on resistance without affecting mean aortic blood pressure and big-ET-1 plasma levels. This is related to the direct increased indices of ventricular performance. Our results competitive deplacement of ET-1 from ET receptors by are, however, in accordance with the results of Teerlink et bosentan [32] . This similarity in ET receptor blockade al [22] who reported that the acute administration of level at three stages was, however, associated with inbosentan lowered blood pressure in rats with chronic HF creased hemodynamic effects of bosentan. This suggests induced by myocardial infraction. Our results are also in an increased role of ET in the vasoconstriction occuring agreement with those of Kiowski et al [11] who provided during the development of HF.
ET antagonism during the development of heart failure. 
